More importantly, NUDCD1 possessed significant mutation differences between responders and non-responders of ipilimumab therapy in melanoma patents suggesting that the therapeutic effect of this mAb may be predicted by NUDCD1 mutations. This evidence concerns the gene NUDCD1 and melanoma.